No Data
Further Weakness as EyePoint Pharmaceuticals (NASDAQ:EYPT) Drops 12% This Week, Taking Five-year Losses to 54%
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
Capital One Financial analyst Tim Chiang maintains $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success
EyePoint Pharmaceuticals Announces Board Changes and New Appointments
Express News | EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
EyePoint Pharmaceuticals Price Target Announced at $15.00/Share by Jefferies
Jefferies Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $15
Jefferies analyst Kambiz Yazdi initiates coverage on $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and sets the target price at $15.According to TipRanks data, the analyst has a success